Show simple item record

dc.contributor.authorWu, Fangxia
dc.contributor.authorDong, Kai
dc.contributor.authorZhu, Meng
dc.contributor.authorZhang, Qinghua
dc.contributor.authorXie, Bingying
dc.contributor.authorLi, Duxin
dc.contributor.authorGan, Hao
dc.contributor.authorLinhardt, Robert J.
dc.contributor.authorZhang, Zhenqing
dc.identifier.citationDevelopment of a method to analyze the complexes of enoxaparin and platelet factor 4 with size-exclusion chromatography, F. Wu, K. Dong, M. Zhu, Q. Zhang, B. Xie, D. Li, H. Gan, R.J. Linhardt, Z. Zhang, Journal of Pharmaceutical and Biomedical Analalysis 164, 668-671, 2019.
dc.descriptionJournal of Pharmaceutical and Biomedical Analalysis 164, 668-671
dc.descriptionNote : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
dc.description.abstractHeparin, a highly sulfated glycosaminoglycan, has been used as a clinical anticoagulant over 80 years. However, heparin-induced thrombocytopenia and thrombosis (HITT) is a serious side effect of heparin therapy, resulting in relatively high risk of amputation and even death. HITT is caused by forming of complexes between heparin and platelet factor 4 (PF4). Enoxaparin, one of the most commonly used low molecular weight heparin (LMWH), were developed in 1980's. The lower molecular weight of enoxaparin reduces the risk of HITT by binding to less PF4. To detect the binding capacity between enoxaparin and PF4 could be an effect way to control this risk before it goes to patients. In this work, a size exclusion chromatography (SEC) method was developed to analyze the patterns of complexes formed between PF4 and enoxaparin. The chromatographic condition was optimized to separate PF4, enoxaparin, ultra-large complexes and small complexes. The linearity and stability of this method were confirmed. The impacts of PF4/enoxaparin mixture ratios and incubation time on the forming complexes were investigated. Four enoxaparin samples were analyzed with this method to verify its practicability. It is a robust, accurate and practicable method, and provides an easy way to monitor the capacity of enoxaparin forming complexes with PF4, suggesting the HITT related quality of enoxaparin.
dc.description.sponsorshipNational Natural Science Foundation of China
dc.relation.ispartofThe Linhardt Research Labs Online Collection
dc.relation.ispartofRensselaer Polytechnic Institute, Troy, NY
dc.relation.ispartofJournal of Pharmaceutical and Biomedical Analysis
dc.subjectChemistry and chemical biology
dc.subjectChemical and biological engineering
dc.subjectBiomedical engineering
dc.titleDevelopment of a method to analyze the complexes of enoxaparin and platelet factor 4 with size-exclusion chromatography
dc.rights.holderIn Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
dc.relation.departmentThe Linhardt Research Labs.
dc.relation.departmentThe Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record